Diagnosed Lifetime Prevalence of Schizophrenia per 1,000 Adults in 2021 and 2041
Relative Sizes of the Factors Contributing to the Trend in Diagnosed Lifetime Prevalent Cases of Schizophrenia over the Next 20 Years
Number of Additional Diagnosed Lifetime Prevalent Cases of Schizophrenia Across the Countries Under Study Due to Trends in Risk or Survival in 2041
Lifetime Prevalent Cases
Diagnosed Lifetime Prevalent Cases
Positive and Negative Symptom Status
Comorbid Cognitive Impairment
Studies Included in the Analysis of Schizophrenia
Studies Excluded from the Analysis of Schizophrenia
Risk/Protective Factors for Schizophrenia
Harinder Kumar, B.D.S., M.P.H., is an associate epidemiologist at Clarivate. His areas of interest are cancer and psychiatric epidemiology. Previously, Dr. Kumar worked with the government of Punjab, National Health Mission, India. He received his M.P.H. from the Tata Institute of Social Sciences in Mumbai. He holds a B.D.S. in dentistry from the National Dental College and Hospital in Punjab.
Alexandre Vo Dupuy, Pharm.D., M.Sc.
Alexandre Vo Dupuy, M.Sc., Pharm.D., is a principal epidemiologist at Clarivate. Previously, he worked in the fields of consulting and real-world evidence and at a major pharmaceutical company. He obtained his doctor of pharmacy from Descartes University in Paris and his master’s degree in pharmacoepidemiology from the University of Bordeaux. He has worked in multiple therapy areas, with a focus on cancer epidemiology. He also codeveloped a scenario-based forecast for COVID-19.